IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

In early October, the FDA granted accelerated approval for pembrolizumab (Keytruda) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease continued to progress after other treatments, and with tumors that have a protein called PD-L1.

"This is great news for patients and physicians working together on lung cancer treatment plans," said Dr. Fred R. Hirsch, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine and CEO of the IASLC. "This drug represents important progress in the lung cancer treatment that can extend lifespans and make a real difference."

Personalized medicine - treating patients with therapies based on the molecular characteristics of a patient's tumor - can add many months or years for those patients whose tumors harbor specific abnormalities. Doctors then treat patients with therapies specifically targeting these abnormalities. Therefore, molecular characterization ("testing") of the patient's tumor is crucial for the right choice of therapy.

"These days, we are discovering several new active drugs for patients with lung cancer and we are getting closer to finding ways to make lung cancer a treatable, chronic disease." Dr. Hirsch said.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients